Cargando…

Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?

STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To determine if local administration of liposomal bupivacaine (LB) reduces postoperative pain scores and narcotic use in spinal deformity patients. METHODS: Adult patients undergoing elective spinal fusion (7 or more levels) for scoliosis or kypho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Andrew S., Crandall, Dennis, Revella, Jan, Adeniyi, Biodun, Chang, Yu Hui H., Chang, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258814/
https://www.ncbi.nlm.nih.gov/pubmed/32677519
http://dx.doi.org/10.1177/2192568220931053
_version_ 1783718566643630080
author Chung, Andrew S.
Crandall, Dennis
Revella, Jan
Adeniyi, Biodun
Chang, Yu Hui H.
Chang, Michael S.
author_facet Chung, Andrew S.
Crandall, Dennis
Revella, Jan
Adeniyi, Biodun
Chang, Yu Hui H.
Chang, Michael S.
author_sort Chung, Andrew S.
collection PubMed
description STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To determine if local administration of liposomal bupivacaine (LB) reduces postoperative pain scores and narcotic use in spinal deformity patients. METHODS: Adult patients undergoing elective spinal fusion (7 or more levels) for scoliosis or kyphosis were selected for inclusion. Patients received either periincisional injections of combined liposomal and standard bupivacaine (n = 90, group L) or standard bupivacaine only (n = 69, group C). Perioperative pain scores (VAS [visual analogue scale]), opioid use, length of stay, functional outcome (ODI [Oswestry Disability Index]), and perioperative complications were recorded. No external funding was received for this study. RESULTS: A total of 159 patients met inclusion criteria (mean age was 54.2 years of age). No significant baseline demographic differences were noted between the 2 groups. Group L experienced slight improvements in pain control on postoperative day (POD) 1 (P = .02). No difference in pain scores were otherwise noted. Group L transitioned off of intravenous (IV) narcotics faster with 52.6% less IV use by POD3 (P = .03). No differences in total narcotic consumption, perioperative complications, lengths of stay, and functional outcome scores were otherwise noted between the 2 cohorts. CONCLUSIONS: The use of LB in adult spinal deformity surgery does not appear to provide clinically important improvements in postoperative pain at the manufacturer’s recommended dosage. Furthermore, while patients receiving LB may transition more quickly off of IV narcotics, this does not appear to translate into an overall decrease in narcotic consumption, hasten return of bowel function, or decrease hospital lengths of stay. Future prospective randomized control trials are warranted. The use of varying dosages of LB may also help further clarify the true efficacy of LB in the setting of spinal deformity surgery.
format Online
Article
Text
id pubmed-8258814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82588142021-07-16 Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery? Chung, Andrew S. Crandall, Dennis Revella, Jan Adeniyi, Biodun Chang, Yu Hui H. Chang, Michael S. Global Spine J Original Articles STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To determine if local administration of liposomal bupivacaine (LB) reduces postoperative pain scores and narcotic use in spinal deformity patients. METHODS: Adult patients undergoing elective spinal fusion (7 or more levels) for scoliosis or kyphosis were selected for inclusion. Patients received either periincisional injections of combined liposomal and standard bupivacaine (n = 90, group L) or standard bupivacaine only (n = 69, group C). Perioperative pain scores (VAS [visual analogue scale]), opioid use, length of stay, functional outcome (ODI [Oswestry Disability Index]), and perioperative complications were recorded. No external funding was received for this study. RESULTS: A total of 159 patients met inclusion criteria (mean age was 54.2 years of age). No significant baseline demographic differences were noted between the 2 groups. Group L experienced slight improvements in pain control on postoperative day (POD) 1 (P = .02). No difference in pain scores were otherwise noted. Group L transitioned off of intravenous (IV) narcotics faster with 52.6% less IV use by POD3 (P = .03). No differences in total narcotic consumption, perioperative complications, lengths of stay, and functional outcome scores were otherwise noted between the 2 cohorts. CONCLUSIONS: The use of LB in adult spinal deformity surgery does not appear to provide clinically important improvements in postoperative pain at the manufacturer’s recommended dosage. Furthermore, while patients receiving LB may transition more quickly off of IV narcotics, this does not appear to translate into an overall decrease in narcotic consumption, hasten return of bowel function, or decrease hospital lengths of stay. Future prospective randomized control trials are warranted. The use of varying dosages of LB may also help further clarify the true efficacy of LB in the setting of spinal deformity surgery. SAGE Publications 2020-06-22 2021-07 /pmc/articles/PMC8258814/ /pubmed/32677519 http://dx.doi.org/10.1177/2192568220931053 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc-nd/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Chung, Andrew S.
Crandall, Dennis
Revella, Jan
Adeniyi, Biodun
Chang, Yu Hui H.
Chang, Michael S.
Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title_full Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title_fullStr Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title_full_unstemmed Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title_short Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal Deformity Surgery?
title_sort does local administration of liposomal bupivacaine reduce pain and narcotic consumption in adult spinal deformity surgery?
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258814/
https://www.ncbi.nlm.nih.gov/pubmed/32677519
http://dx.doi.org/10.1177/2192568220931053
work_keys_str_mv AT chungandrews doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery
AT crandalldennis doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery
AT revellajan doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery
AT adeniyibiodun doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery
AT changyuhuih doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery
AT changmichaels doeslocaladministrationofliposomalbupivacainereducepainandnarcoticconsumptioninadultspinaldeformitysurgery